World Leaders
Behind the scenes of our patient clinic’s elegant luxury is a world of scientific innovation and discovery led by a team of world-class researchers. Since 2000, our research team has completed more than 60 studies, involving over 1,900 participants and helping multiple products get to market, including; Belkyra, Botox, Juvederm, Latisse, Dysport, Xeomin, and Radiesse. In fact, we have enrolled more participants and successfully completed more studies than any other cosmetic research facility in Canada. This deep understanding of the science and evidence behind our treatments and products allows our staff to bring an unparalleled level of expertise to patients.
Clinical Research Studies
Interested in learning more about the globally recognized research conducted at Humphrey Cosmetic Dermatology? Here is a selection of the studies completed on-site by our clinical research team.
-
MT10109L-005
Allergan Inc.
2018MT10109L-005 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines
-
Protocol CMO-US-FAS-0486
Allergan Inc.
2017-2018 (Current)Protocol CMO-US-FAS-0486 Histological and Microbiological Evaluation of Late Occurring Nodules with Hyaluronic Acid Dermal Fillers
-
Protocol 1620303
Revance Therapeutics
2017-2018Protocol 1620303 An open-label, multi-center trial to assess the safety of single and repeat treatment of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar lines (SAKURA open-label safety)
-
New Botulinum Toxin Type A for (Glabella) Frown Lines (FDA Approval Pending)
Revance Therapeutics
2015A Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines.
Completed 2015 -
191622-130 Phase 2
Allergan Inc.
2014 - 201591622-130 Phase 2 study to evaluate the safety and efficacy of a range of doses of BOTOX for the treatment of subjects with bilateral masseter muscle hypertrophy (MMH)
-
BELKYRA 3 Year Follow-up
Kythera Biopharmaceuticals, Inc.
September 2015ATX-101-13-35: A Multicenter, Double-blind, Non-treatment, Long-term Follow-up Study of Subjects who Completed the ATX-101 (Deoxycholic Acid Injection) Clinical Trials ATX-101-11-22 or ATX-101-11-23 for the Reduction of Localized Subcutaneous fat in the Submental Area.
-
Eyebrow Study
Allergan Medical Inc.
July 2014Protocol: 192024-043: Bimatoprost for the Treatment of Eyebrow Hypotrichosis
-
BELKYRA for Submental Fat (FDA Approved)
Kythera Biopharmaceuticals
September 2013BELKYRA for Submental Fat (FDA Approved)
Protocol ATX-101-11-22: Multicenter, randomized, double-blind, placebo-controlled Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area.
Completed September 2013 -
A 10 Year Safety Review Botox
Allergan Medical Inc.
March 2013GMA-BTXC-11-004: Long-Term Safety and Patient Satisfaction of Effectiveness of Facial Aesthetic Treatment with BOTOX®; A 10 Year International Experience.
Completed March 2013 -
Botox for Forehead and Glabellar Combined
Allergan Medical Inc.
March 2012Protocol: GMA-BTXC-10-002: A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group, Single Treatment Cycle Study of BOTOX® Cosmetic (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Forehead and Glabellar Rhytides.
-
Juvederm Voluma for Cheek Augmentation (FDA Approved)
Allergan Medical Inc.
2012Voluma-002: A Multicenter, Single-blind, Randomized, “no-treatment” Control Study of the safety and Effectiveness of JUVÉDERM® VOLUMA XC Injection Gel for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face
-
Subject Satisfaction Botox Crow’s Feet and Glabellar
Allergan Medical Inc.
August 2011Protocol: 191622/099:A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines)
-
Lidocaine Used for IPL Treatment
Carruthers Dermatology Centre, Inc.
February 2009CDC 08-01: A Single Centre Controlled Comparison Study to Evaluate the Safety of Lidocaine 15% and Prilocaine 5% Topical Ointment used as Anaesthesia for Intense Pulsed Light Treatments.
-
Latisse for Eyelash Prominence (FDA Approval)
Allergan Medical Inc.
October 2007Protocol:192024-032-00: A Multicenter, Double-Masked, Randomized, Parallel Study Assessing the Safety and Efficacy of Once-Daily Application of Bimatoprost Solution Compared to Vehicle in Increasing Overall Eyelash Prominence
-
Botox for Axillary Hyperhidrosis in Adolescents (FDA Approved)
Allergan Medical Inc.
September 2007No. 191622-075-00: A Multicenter, Open-Label Study of the Safety and Efficacy of Repeated Treatments with BOTOX (Botulinum Toxin Type A) for Primary Axillary Hyperhidrosis in Adolescents
-
Xeomin New Botulinum Toxin Type A (FDA Approval)
Merz Pharmaceuticals GMBH
August 2007Protocol # 60201-0527/1: A prospective, randomized, double-blind, placebo-controlled, multicenter trial to determine the optimal dose of NT 201, free of complexing proteins, in the treatment of glabellar frown lines.
-
SilSkin Silicone Oil for HIV Associated Facial Lipoatrophy
RJ Development
November 2004A Clinical Trial to determine the safety and effectiveness of microdroplet injections of SilSkin Silicone oil for HIV associated facial lipoatrophy.
-
Botox Upper Face
Allergan Medical Inc.
September 2004Protocol No. BTX 9920, A Single Center, Pilot, Dose-Comparison Study of Safety and Efficacy of BOTOX Cosmetic (Botulinum Toxin Type A) in Female Subjects with Upper Face Rhytids
-
Botox Long Term Follow-up Safety Study
Allergan Medical Inc.
November 2003Protocol No. BTX 9917, A Long Term Safety Review of Subjects Treated with BOTOX (Botulinum Toxin Type A) for Cosmetic Use.
-
Botox Axillary Hyperhidrosis (FDA Approved)
Allergan Medical Inc.
August 2002A multicentre, double-blind, randomized, placebo-controlled, parallel study of the safety and efficacy of repeated treatment with one or two doses of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Primary Axillary Hyperhidrosis Protocol No. 19162-016.
-
Botox Dilution
Allergan Medical Inc.
November 2001A prospective, double blind randomized, parallel group study analyzing the effect of varying BOTOX dilution in female subjects with glabellar rhytids.
-
Botox Dose Range for Forehead Lines (Female)
Allergan Medical Inc.
November 2001A prospective, double blind randomized, parallel group, dose-ranging study of BOTOX in female subjects with horizontal forehead rhytids
-
Botox Dosing Range (FDA Approved)
Allergan Medical Inc.
May 2000A prospective, double blind, randomized parallel group, dose-ranging study of BOTOX in female subjects with glabellar rhytids.
Clinical Research Team
Natalie Croll
Clinical Research Coordinator, LPN
Beauty philosophy: Beauty is the glow we give off when we find that place of self-love.
Emma Jennings
Clinical Research Coordinator, BSc
Beauty philosophy: Beauty is what we exude when we feel confident in ourselves.